JP2023503868A - インターロイキン１５融合タンパク質およびプロドラッグ、ならびにそれらの組成物および方法 - Google Patents

インターロイキン１５融合タンパク質およびプロドラッグ、ならびにそれらの組成物および方法 Download PDF

Info

Publication number
JP2023503868A
JP2023503868A JP2022528714A JP2022528714A JP2023503868A JP 2023503868 A JP2023503868 A JP 2023503868A JP 2022528714 A JP2022528714 A JP 2022528714A JP 2022528714 A JP2022528714 A JP 2022528714A JP 2023503868 A JP2023503868 A JP 2023503868A
Authority
JP
Japan
Prior art keywords
fusion protein
cells
tumor
complex
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022528714A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023503868A5 (https=
Inventor
ワン，ヤン
Original Assignee
イミューン ターゲティング インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イミューン ターゲティング インク． filed Critical イミューン ターゲティング インク．
Publication of JP2023503868A publication Critical patent/JP2023503868A/ja
Publication of JP2023503868A5 publication Critical patent/JP2023503868A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2022528714A 2019-12-05 2020-12-04 インターロイキン１５融合タンパク質およびプロドラッグ、ならびにそれらの組成物および方法 Pending JP2023503868A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962944203P 2019-12-05 2019-12-05
US62/944,203 2019-12-05
PCT/US2020/063214 WO2021113577A1 (en) 2019-12-05 2020-12-04 Interleukin 15 fusion proteins and prodrugs, and compositions and methods thereof

Publications (2)

Publication Number Publication Date
JP2023503868A true JP2023503868A (ja) 2023-02-01
JP2023503868A5 JP2023503868A5 (https=) 2023-12-08

Family

ID=76222692

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022528714A Pending JP2023503868A (ja) 2019-12-05 2020-12-04 インターロイキン１５融合タンパク質およびプロドラッグ、ならびにそれらの組成物および方法

Country Status (5)

Country Link
US (1) US20220402988A1 (https=)
EP (1) EP4069725A4 (https=)
JP (1) JP2023503868A (https=)
CN (1) CN115315434A (https=)
WO (1) WO2021113577A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021207669A1 (en) 2020-04-10 2021-10-14 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
JP2023540629A (ja) * 2020-09-16 2023-09-25 ベイジーン リミテッド インターロイキン１５構築物及び使用方法
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
WO2022144632A1 (en) 2020-12-30 2022-07-07 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into nk cells
BR112023018735A2 (pt) 2021-03-16 2023-11-28 Cytomx Therapeutics Inc Construtos de citocinas ativáveis mascarados e composições e métodos relacionados
US20230035308A1 (en) * 2021-07-02 2023-02-02 Aetio Biotherapy, Inc. Activatable monomeric cytokine-single chain (sc) fc fusion proteins and uses thereof
CA3238283A1 (en) * 2021-11-15 2023-05-19 Yangxin Fu Fusion protein construct taking interleukin 15 as active ingredient and use thereof
JP2025507733A (ja) * 2022-02-28 2025-03-21 ウーシー バイオロジクス アイルランド リミテッド Ｉｌ－１５変異体を含むヘテロ二量体ポリペプチド錯体とその使用
EP4695281A1 (en) * 2023-04-12 2026-02-18 CytomX Therapeutics, Inc. Masking polypeptides, activatable cytokine constructs, and related compositions and methods
CN120936384A (zh) * 2023-04-12 2025-11-11 西托姆克斯治疗公司 掩蔽多肽、可活化细胞因子构建体以及相关组合物和方法
WO2025113255A1 (zh) * 2023-11-28 2025-06-05 北京昌平实验室 抗肿瘤抗体与白介素15前体的双功能复合分子及其应用

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0367588A (ja) * 1989-03-07 1991-03-22 Boehringer Ingelheim Internatl Gmbh 組換えタンパク質レセプター
JP2003507012A (ja) * 1999-08-09 2003-02-25 レキシジェン ファーマシューティカルズ コーポレイション 複合サイトカイン−抗体複合体
JP2009512433A (ja) * 2005-10-20 2009-03-26 アンスティテュ ナシオナル ド ラ サント エ ド ラ ルシュルシェ メディカル（アンセルム） Ｉｌ−１５ｒベータ／ガンマを介したｉｌ−１５活性の選択的かつ強力なエンハンサーとしてのｉｌ−１５ｒアルファスシドメイン、およびハイパーアゴニスト（ｉｌ１５ｒアルファスシ−ｉｌ１５）融合タンパク質
US20130089516A1 (en) * 2010-04-02 2013-04-11 University Of Rochester Protease activated cytokines
JP2013541335A (ja) * 2010-09-21 2013-11-14 アルター・バイオサイエンス・コーポレーション 多量体ｉｌ−１５可溶性融合分子並びにその製造及び使用方法
JP2016525881A (ja) * 2013-05-14 2016-09-01 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 改変キメラ抗原受容体（ｃａｒ）ｔ細胞のヒト応用
JP2016532693A (ja) * 2013-08-08 2016-10-20 サイチューン・ファーマＣｙｔｕｎｅ Ｐｈａｒｍａ ＩＬ−１５及びＩＬ−１５Ｒαスシドメインに基づくモジュロカイン
WO2019006472A1 (en) * 2017-06-30 2019-01-03 Xencor, Inc. TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS
WO2019213517A1 (en) * 2018-05-04 2019-11-07 Immune Targeting Inc. Interleukin 15 fusion proteins, and compositions and therapeutic methods thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220002370A1 (en) * 2018-09-27 2022-01-06 Xilio Development, Inc. Masked cytokine polypeptides
CA3141626A1 (en) * 2019-06-12 2020-12-17 AskGene Pharma, Inc. Novel il-15 prodrugs and methods of use thereof

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0367588A (ja) * 1989-03-07 1991-03-22 Boehringer Ingelheim Internatl Gmbh 組換えタンパク質レセプター
JP2003507012A (ja) * 1999-08-09 2003-02-25 レキシジェン ファーマシューティカルズ コーポレイション 複合サイトカイン−抗体複合体
JP2009512433A (ja) * 2005-10-20 2009-03-26 アンスティテュ ナシオナル ド ラ サント エ ド ラ ルシュルシェ メディカル（アンセルム） Ｉｌ−１５ｒベータ／ガンマを介したｉｌ−１５活性の選択的かつ強力なエンハンサーとしてのｉｌ−１５ｒアルファスシドメイン、およびハイパーアゴニスト（ｉｌ１５ｒアルファスシ−ｉｌ１５）融合タンパク質
US20130089516A1 (en) * 2010-04-02 2013-04-11 University Of Rochester Protease activated cytokines
JP2013541335A (ja) * 2010-09-21 2013-11-14 アルター・バイオサイエンス・コーポレーション 多量体ｉｌ−１５可溶性融合分子並びにその製造及び使用方法
JP2016525881A (ja) * 2013-05-14 2016-09-01 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 改変キメラ抗原受容体（ｃａｒ）ｔ細胞のヒト応用
JP2016532693A (ja) * 2013-08-08 2016-10-20 サイチューン・ファーマＣｙｔｕｎｅ Ｐｈａｒｍａ ＩＬ−１５及びＩＬ−１５Ｒαスシドメインに基づくモジュロカイン
WO2019006472A1 (en) * 2017-06-30 2019-01-03 Xencor, Inc. TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS
WO2019213517A1 (en) * 2018-05-04 2019-11-07 Immune Targeting Inc. Interleukin 15 fusion proteins, and compositions and therapeutic methods thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANNU. REV. IMMUNOL., vol. 11, JPN6024041851, 1993, pages 245 - 267, ISSN: 0005440459 *
NATURE IMMUNOLOGY, vol. 8, no. 9, JPN6024041852, 2007, pages 1001 - 1007, ISSN: 0005440460 *

Also Published As

Publication number Publication date
CN115315434A (zh) 2022-11-08
EP4069725A1 (en) 2022-10-12
EP4069725A4 (en) 2024-01-10
WO2021113577A1 (en) 2021-06-10
US20220402988A1 (en) 2022-12-22

Similar Documents

Publication Publication Date Title
JP7684047B2 (ja) インターロイキン１５融合タンパク質、およびその組成物ならびに治療方法
JP2023503868A (ja) インターロイキン１５融合タンパク質およびプロドラッグ、ならびにそれらの組成物および方法
US12473337B2 (en) Homodimeric or heterodimeric interleukin 12 fusion proteins, and compositions and therapeutic methods thereof
US10822419B2 (en) Masking chimeric antigen receptor T cells for tumor-specific activation
JP6484634B2 (ja) Ｉｌ−１５ヘテロ二量体タンパク質及びその用途
EP3160498B1 (en) Il-15-based molecules and methods of use thereof
CN118451096A (zh) 异二聚体fc细胞因子及其用途
WO2022015711A1 (en) Fusion proteins of anti-pd-l1 and attenuated interferon, and compositions and therapeutic methods thereof
CA3179414A1 (en) Human immune cells genomically modified to express orthogonal receptors
KR20220137630A (ko) Il-7 단백질과 car-보유 면역 세포의 조합물로 고형 종양을 치료하는 방법
KR20220150274A (ko) Il-7 단백질과 이중특이적 항체의 조합물을 사용한 종양의 치료 방법
JP2022511885A (ja) ヒト抗ａｎｔｘｒキメラ抗原受容体及びその用途
JP2022528422A (ja) インターロイキン２（ｉｌ２）およびインターフェロン（ｉｆｎ）を含む治療
JP2026501506A (ja) Ｃｌｄｎ１８．２及びｃｄ３に結合する二重特異性結合剤並びに免疫チェックポイント阻害剤を含む併用療法
US20260070957A1 (en) Interleukin 15 fusion proteins, and compositions and therapeutic methods thereof
RU2757502C1 (ru) Генетическая кассета, содержащая кодон-оптимизированные нуклеотидные последовательности генов TRAIL, PTEN и IFNβ-1, и фармацевтическая композиция для лечения онкологических заболеваний
HK40050872A (en) Interleukin 15 fusion proteins, and compositions and therapeutic methods thereof
HK40050873A (en) Interleukin 12 fusion proteins, and compositions and therapeutic methods thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231130

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241016

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241017

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250313

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250512